Bulk Pharmaceutical API Sources for VISIPAQUE 270

Bulk Pharmaceutical API Sources for VISIPAQUE 270

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		3724
Hangzhou APIChem Technology		AC-7610
ABI Chem		AC1L1GKH
ChemMol		30112843
ChemMol		49403217
Amadis Chemical		A844203
AKos Consulting & Solutions		AKOS015895607

Bulk Active Pharmaceutical Ingredient (API) Sources for: VISIPAQUE 270

Last updated: July 28, 2025

---

Introduction

VISIPAQUE 270, a clinical radiology contrast agent primarily containing iohexol, is widely used in computed tomography (CT) imaging to enhance diagnostic accuracy. As a nonionic, water-soluble contrast medium, its efficacy and safety hinge critically on the quality and sourcing of its active pharmaceutical ingredient (API), iohexol. This article examines the global landscape of API suppliers for VISIPAQUE 270, highlighting key manufacturers, sourcing strategies, regulatory considerations, and market dynamics influencing procurement decisions.

---

Understanding Iohexol as the API for VISIPAQUE 270

Iohexol, chemically known as 2,3,5-triiodobenzoic acid,, 2,3,5-triiodobenzoic acid, 20-iodo-2-propoxyl-1,3,4,-benzotriazine-1,4-dione, is the API that defines VISIPAQUE 270's pharmacological and chemical characteristics. It is characterized by high iodine content, water solubility, and low toxicity. The API quality directly impacts the final product's safety, efficacy, regulatory approval, and patient outcomes.

Major API Manufacturing Regions and Key Players

The primary regions producing iohexol encompass North America, Europe, and Asia. Each region has prominent manufacturers, frequently serving both domestic and international markets.

North American API Suppliers

• GE Healthcare (U.S.): As the original developer of VISIPAQUE, GE Healthcare produces its own API. This vertically integrated supply chain ensures consistency, although it limits external sourcing of the API for the brand.
• Baxter International (U.S.): While primarily focused on final formulation, Baxter occasionally sources APIs for internal use, particularly in generic markets.

European API Manufacturers

• BASF (Germany): One of the leading global chemical and pharmaceutical API manufacturers, BASF supplies iohexol to various pharmaceutical firms worldwide. Their high-quality standards align with regulatory requirements such as EMA approvals.
• Viatris (formerly Mylan, Netherlands): Offers generic iohexol APIs, supplying to a broad spectrum of generic contrast agent producers.
  Note: European manufacturers often provide APIs for both branded and generic contrast agents, with robust regulatory oversight from EMA and other agencies.

Asian API Manufacturers

• Luoxin Pharmaceutical Group (China): An established manufacturer of iohexol API, fulfilling both domestic and export demands.
• Shandong Luoxin Pharmaceutical Group (China): Has expanded production capacity to meet global demand, with facilities compliant with GMP standards.
• Dao Jiang Men Libang Pharmaceutical Co. Ltd. (China): A relatively newer entrant focusing on cost-efficient API production, though maintaining adherence to international quality standards.

Asian firms typically offer competitive pricing, making them significant suppliers for generic contrast agents. They are increasingly gaining regulatory approvals, facilitating their entry into mature markets.

API Sourcing Strategies for VISIPAQUE 270

Given the complex regulatory landscape, formulators and manufacturers pursue various sourcing strategies:

• Vertical Integration: Original developers like GE Healthcare produce their own API, ensuring tight quality control.
• Strategic Partnerships: Branding entities partner with established API producers for consistent supply and regulatory compliance.
• Global Procurement: Large pharmaceutical companies diversify sources across multiple regions to mitigate supply chain disruptions, adapt to regional pricing dynamics, and ensure compliance with local regulations.

Importantly, the choice of API supplier influences regulatory status, cost, and supply chain stability. Variability in manufacturing capacity, geopolitical factors, and regulatory approvals modify procurement decisions.

Regulatory Considerations Impacting API Sourcing

Regulatory agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and China's National Medical Products Administration (NMPA) impose strict GMP standards on API manufacturing. Suppliers must demonstrate:

• Quality Compliance: Stringent quality control, stability, and purity assessments.
• Documentation & Traceability: Comprehensive batch records and validated supply chains.
• Regulatory Approvals: API suppliers must secure recognized approvals or certificates of suitability (CEP) to meet local requirements.

Inconsistencies or lapses in compliance can lead to supply disruptions or regulatory sanctions. Therefore, sourcing from reliable, approvable manufacturers is paramount.

Market Dynamics and Trends Affecting API Supply for VISIPAQUE 270

• Expansion of Generic Competition: The proliferation of generic iohexol APIs has increased competition, exerting downward pressure on prices but demanding higher quality standards.
• Supply Chain Disruptions: Global events, including pandemics and geopolitical tensions, have stressed API supply chains, prompting manufacturers and formulators to diversify sources.
• Regulatory Stringency & Exceptions: Enhanced quality requirements incentivize sourcing from established suppliers with proven compliance records.
• Environmental & Sustainability Pressures: Increasing focus on environmentally sustainable manufacturing practices influences supplier selection, favoring greener, GMP-compliant operations.
• Pricing and Cost Efficiency: Asian API providers often offer more cost-effective options, though with considerations around quality assurance and logistical reliability.

Key Suppliers and Their Certifications

Top API producers supplying iohexol include:

Manufacturer	Region	Certification & Approvals	Notes
BASF	Europe	EMA CEP, GMP	Premier supplier with global regulatory approvals.
Luoxin Pharmaceutical Group	China	NMPA GMP, domestic approvals	Competitive pricing; expanding global footprint.
Shandong Luoxin Pharmaceutical	China	GMP, CE (certification applicable)	Growing presence in international markets.
Viatris (Mylan)	Europe/Global	EMA CEP, FDA approvals available	Supplies both branded and generic APIs.

Note: Selection depends on regional regulatory acceptability and specific quality certifications.

---

Conclusion

The sourcing landscape for vmage-4520 iohexol API — the active ingredient in VISIPAQUE 270 — is multi-faceted, encompassing a broad global network of manufacturers. While original developers like GE rely on internal supply chains, the dynamics of the global API market involve strategic partnerships with established European players like BASF and growing Asian manufacturers such as Luoxin Pharmaceutical Group. Ensuring quality, regulatory compliance, and supply chain stability remains central to sourcing decisions, particularly amidst rising generic competition and geopolitical risks.

---

Key Takeaways

• Authenticity, purity, and GMP compliance are non-negotiable criteria when sourcing iohexol API for VISIPAQUE 270.
• Major API suppliers are located in Europe (BASF, Viatris), North America (GE), and Asia (Luoxin, Shandong Luoxin), with supply chain diversification vital for risk mitigation.
• Regulatory approvals like EMA CEP, FDA, and NMPA certifications serve as critical quality benchmarks.
• Cost competitiveness from Asian suppliers must be balanced with stringent quality assurance.
• Evolving regulatory landscapes and market dynamics necessitate proactive sourcing strategies aligned with compliance and supply stability.

---

FAQs

Q1: Are there alternative API sources for VISIPAQUE 270 besides the original manufacturer?
Yes. Several generic manufacturers, especially in China and India, produce iohexol APIs. However, sourcing from approved and compliant manufacturers is essential to ensure regulatory acceptance and product safety.

Q2: What regulatory certifications should an API supplier for iohexol possess?
Key certifications include GMP compliance, European CEP, FDA approval if applicable, and NMPA certification for Chinese manufacturers. These ensure the API meets international quality standards.

Q3: How does API quality impact the final VISIPAQUE 270 product?
API quality directly influences efficacy, safety, and regulatory approval. Impurities or deviations can lead to adverse patient outcomes, regulatory sanctions, and product recalls.

Q4: What are the risks associated with sourcing iohexol API from emerging markets?
Risks include inconsistent quality, regulatory non-compliance, supply chain disruptions, and intellectual property concerns. Thorough supplier qualification is necessary.

Q5: How has the global COVID-19 pandemic affected API sourcing for contrast agents?
The pandemic caused supply chain disruptions, delays, and increased scrutiny of manufacturing standards. This has underscored the importance of diversified sourcing and supply chain resilience.

---

References

1. European Medicines Agency (EMA). Certificate of Suitability for Iohexol.
2. U.S. Food and Drug Administration (FDA). API Registration Data for Imaging Agents.
3. BASF Chemical Supplier Profile. Global API Manufacturing Overview.
4. Luoxin Pharmaceutical Group Annual Report. Production Capacity and Regulatory Approvals.
5. World Health Organization (WHO). Good Manufacturing Practices for APIs.